AptaBio Therapeutics Valuation
Is A293780 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A293780 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A293780's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A293780's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A293780?
Key metric: As A293780 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is A293780's PB Ratio? | |
|---|---|
| PB Ratio | 3.6x |
| Book | ₩48.97b |
| Market Cap | ₩177.15b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 52.6x |
| Enterprise Value/EBITDA | -7.9x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does A293780's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.7x | ||
A217330 Cytogen | 2.9x | n/a | ₩160.1b |
A011000 GeneOne Life Science | 2x | n/a | ₩175.6b |
A182400 NKMAX | 1.3x | n/a | ₩172.7b |
A950210 Prestige BioPharma | 0.4x | n/a | ₩174.0b |
A293780 AptaBio Therapeutics | 3.6x | n/a | ₩177.1b |
Price-To-Book vs Peers: A293780 is expensive based on its Price-To-Book Ratio (3.6x) compared to the peer average (1.7x).
Price to Book Ratio vs Industry
How does A293780's PB Ratio compare vs other companies in the KR Biotechs Industry?
Price-To-Book vs Industry: A293780 is expensive based on its Price-To-Book Ratio (3.6x) compared to the KR Biotechs industry average (2.5x).
Price to Book Ratio vs Fair Ratio
What is A293780's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 3.6x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate A293780's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Bioneer
₩521.4b
Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.
A064550
₩20,550.00
7D
1.5%
1Y
-31.5%
Medy-Tox
₩869.0b
Operates as a biopharmaceutical company in South Korea.
A086900
₩131,900.00
7D
0.5%
1Y
-41.1%
Hugel
₩2.9t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩259,000.00
7D
-5.3%
1Y
67.2%